Skip to main content

Sio Gene Therapies, Inc. (SIOX)

NASDAQ: SIOX · Delayed Price · USD
2.27
-0.09 (-3.81%)
Pre-market:Oct 22, 2021 8:41 AM EDT
2.36
0.21 (9.77%)
At close: Oct 21, 4:00 PM
Market Cap188.92M
Revenue (ttm)n/a
Net Income (ttm)-35.70M
Shares Out72.94M
EPS (ttm)-0.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,518,254
Open2.35
Previous Close2.15
Day's Range2.30 - 2.66
52-Week Range1.76 - 4.15
Beta1.66
AnalystsBuy
Price Target7.40 (+213.6%)
Est. Earnings DateNov 11, 2021

About SIOX

Sio Gene Therapies, Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of...

IndustryBiotechnology
Founded2014
CEOPavan Cheruvu
Employees42
Stock ExchangeNASDAQ
Ticker SymbolSIOX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for SIOX stock is "Buy." The 12-month stock price forecast is 7.40, which is an increase of 213.56% from the latest price.

Price Target
$7.40
(213.56% upside)
Analyst Consensus: Buy

News

Sio Gene Therapies Announces Reorganization of R&D Group

Two new executive positions created in connection with departure of R&D Head Two new executive positions created in connection with departure of R&D Head

16 hours ago - GlobeNewsWire

Top Penny Stocks to Buy Now? 3 Under $4 to Watch

These under $4 penny stocks could be worth taking a look at The post Top Penny Stocks to Buy Now? 3 Under $4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:EBONSENS
17 hours ago - PennyStocks

Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene ...

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...

1 day ago - GlobeNewsWire

Sio Gene Shares Gain As Genetic Nerve Cell Disorder Gene Therapy Trial Shows Encouraging Action

Sio Gene Therapies Inc (NASDAQ: SIOX) has announced interim data from its Phase 1/2 study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis. GM...

1 day ago - Benzinga

Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-...

NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of pat...

1 day ago - GlobeNewsWire

3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now

Are these 'must watch' penny stocks on your list right now? The post 3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:SDPISINO
2 weeks ago - PennyStocks

UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss new...

2 weeks ago - GlobeNewsWire

Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021

Oral presentation to discuss new data updates from the high- and low-dose cohorts from the ongoing Phase 1/2 trial of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis Oral presentation to discuss new...

2 weeks ago - GlobeNewsWire

Sio Gene Therapies to Participate in Upcoming Conferences

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve t...

4 weeks ago - GlobeNewsWire

Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2...

-  Study has now enrolled a total of nine patients across low-dose and high-dose cohorts -  On track to report 12-month topline safety, biomarker, and efficacy data from Type II low-dose AXO-AAV-GM1 coh...

1 month ago - GlobeNewsWire

Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones

– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway

4 months ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Sio Gene Therapies (SIOX) Stock?

Investors need to pay close attention to Sio Gene Therapies (SIOX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

3 Robinhood Penny Stocks Under $2 to Watch Next Week

Best Robinhood penny stocks to buy? Check these 3 out for your watchlist The post 3 Robinhood Penny Stocks Under $2 to Watch Next Week appeared first on Penny Stocks to Buy, Picks, News and Information ...

Other symbols:CREXMICT
4 months ago - PennyStocks

Sio Gene Therapies' GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF

Sio Gene Therapies Inc (NASDAQ: SIOX) has announced new biomarker data from Phase 1/2 study of AXO-AAV-GM1, an adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosidosis. T...

5 months ago - Benzinga

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...

5 months ago - InvestorPlace

Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of G...

NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transfor...

5 months ago - GlobeNewsWire

Sio Gene Therapies Provides Update on Cash Position and Major Upcoming GM1 Gangliosidosis Program Milestones

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

7 months ago - GlobeNewsWire

Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve th...

8 months ago - GlobeNewsWire

Sio Gene Therapies Gains After Receiving $11.6M From Arvelle Therapeutics Deal Close

Sio Gene Therapies Inc (NASDAQ: SIOX) has received $11.6 million from closing the sale of Arvelle Therapeutics to Angelini Pharma.

8 months ago - Benzinga

Dosing Underway In Sio Gene's Early-Stage Trial For GM2 Gangliosidosis Gene Therapy

Sio Gene Therapies Inc (NASDAQ: SIOX) has dosed the first patient in Phase 1/2 trial evaluating AXO-AAV-GM2 investigational gene therapy to treat GM2 gangliosidosis, also known as Tay-Sachs or Sandhoff ...

8 months ago - Benzinga

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sand...

- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study through...

8 months ago - GlobeNewsWire

Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase 1/2 Trial of AXO-AAV-GM1...

-  Generally well-tolerated with a favorable safety profile in five patients -  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6, representi...

10 months ago - GlobeNewsWire

Axovant (SIOX) Upgraded to Buy: Here's What You Should Know

Axovant (SIOX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10 months ago - Zacks Investment Research

Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with G...

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform ...

10 months ago - GlobeNewsWire

Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

11 months ago - GlobeNewsWire